DGICB vs GILD · P/E 10, rev $978.0M vs P/E 18, rev $7.80B
Donegal Group B Inc (DGICB) versus Gilead Sciences Inc (GILD) — a side-by-side from cached financials, not a winner call.
Donegal Group B Inc (DGICB) is a insurance - property & casualty company listed on US.
Gilead Sciences Inc (GILD) is a drug manufacturers - general company listed on US. It is led by Daniel P. O'Day.
Latest reported DGICB revenue for 2025-12-31 was $978.0M. Net income was $79.3M. Revenue was down 1.2% from 2024-12-31 to 2025-12-31. DGICB currently screens at market cap $677.6M and trailing P/E 10.3.
Latest reported GILD revenue for 2026-06-30 was $7.80B. Net income was -$10.50B. Revenue was up 12.1% from 2026-03-31 to 2026-06-30. GILD currently screens at market cap $160.15B and trailing P/E 17.5.
DGICB currently screens at market cap $677.6M and trailing P/E 10.3. GILD currently screens at market cap $160.15B and trailing P/E 17.5.
Not investment advice. Open the DGICB and GILD stock pages for the full models.
Not investment advice.